EGFR has a tumour-promoting role in liver macrophages during hepatocellular carcinoma formation. - Wikidata - awgldk - TriplyDB

EGFR has a tumour-promoting role in liver macrophages during hepatocellular carcinoma formation.

EGFR has a tumour-promoting role in liver macrophages during hepatocellular carcinoma formation.

http://www.wikidata.org/entity/Q34282375

about

Tissue- and Serum-Associated Biomarkers of Hepatocellular Carcinoma Mechanisms underlying skin disorders induced by EGFR inhibitors EGFR Signaling in Liver Diseases The Tyrosine Kinase Inhibitor Gefitinib Restricts Mycobacterium tuberculosis Growth through Increased Lysosomal Biogenesis and Modulation of Cytokine Signaling.EGFR kinase activity is required for TLR4 signaling and the septic shock response.Serum Metabolomics to Identify the Liver Disease-Specific Biomarkers for the Progression of Hepatitis to Hepatocellular Carcinoma.Loss of hepatocyte ERBB3 but not EGFR impairs hepatocarcinogenesis Sex Difference of Egfr Expression and Molecular Pathway in the Liver: Impact on Drug Design and Cancer Treatments?Genome-wide association study identified PLCE1- rs2797992 and EGFR- rs6950826 were associated with TP53 expression in the HBV-related hepatocellular carcinoma of Chinese patients in Guangxi EGFR regulates macrophage activation and function in bacterial infection.Impact of myeloid-derived suppressor cell on Kupffer cells from mouse livers with hepatocellular carcinoma Intratumoral CD3 and CD8 T-cell Densities Associated with Relapse-Free Survival in HCC.STAT3 overexpression promotes metastasis in intrahepatic cholangiocarcinoma and correlates negatively with surgical outcome FGFR3, as a receptor tyrosine kinase, is associated with differentiated biological functions and improved survival of glioma patients.Changes in lncRNAs and related genes in β-thalassemia minor and β-thalassemia major.Activation of Epidermal Growth Factor Receptor in Macrophages Mediates Feedback Inhibition of M2 Polarization and Gastrointestinal Tumor Cell Growth.Killers creating new life: caspases drive apoptosis-induced proliferation in tissue repair and disease.Dual Shp2 and Pten Deficiencies Promote Non-alcoholic Steatohepatitis and Genesis of Liver Tumor-Initiating Cells.Tumor regulation of the tissue environment in the liver.Role of ADAM10 in intestinal crypt homeostasis and tumorigenesis.Long noncoding RNA GIHCG promotes hepatocellular carcinoma progression through epigenetically regulating miR-200b/a/429.Brief Report: The Deletion of the Phosphatase Regulator NIPP1 Causes Progenitor Cell Expansion in the Adult Liver.IRE1α inhibition by natural compound genipin on tumour associated macrophages reduces growth of hepatocellular carcinoma.Hepatic stellate cells as key target in liver fibrosis.[Guidelines for vaccination of immunocompromised individuals].Dissecting the role of epidermal growth factor receptor catalytic activity during liver regeneration and hepatocarcinogenesis.Oxidative stress mediates an increased formation of vascular endothelial growth factor in human hepatocarcinoma cells exposed to erlotinib.Ginsenoside Rh2 Targets EGFR by Up-Regulation of miR-491 to Enhance Anti-tumor Activity in Hepatitis B Virus-Related Hepatocellular Carcinoma.Cell-type specific functions of epidermal growth factor receptor are involved in development of hepatocellular carcinoma.Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine.The Immune System's Contribution to the Clinical Efficacy of EGFR Antagonist Treatment.Elevated AEG-1 expression in macrophages promotes hypopharyngeal cancer invasion through the STAT3-MMP-9 signaling pathway.Matrine increases the inhibitory effects of afatinib on H1975 cells via the IL‑6/JAK1/STAT3 signaling pathway.Liver inflammation and cancer: The role of tissue microenvironment in generating the tumor-promoting niche (TPN) in the development of hepatocellular carcinoma.Preventive Inhibition of Liver Tumorigenesis by Systemic Activation of Innate Immune Functions.Growth arrest and DNA damage-inducible protein (GADD34) enhanced liver inflammation and tumorigenesis in a diethylnitrosamine (DEN)-treated murine model.Targeted Therapies: Immunologic Effects and Potential Applications Outside of Cancer.A model of dormant-emergent metastatic breast cancer progression enabling exploration of biomarker signatures.Application of EGFR inhibitor reduces circulating tumor cells during transcatheter arterial embolization.Cell type-specific pharmacological kinase inhibition for cancer chemoprevention.

P2860

Q26743361-60911402-68E1-42E0-BDD7-B18DBD349945 Q26745689-4E270CDE-E284-4379-9AE8-6F4E67C7AEFA Q26771265-0D3CFC0A-BE57-4CC0-8D41-946392271EA2 Q30402360-F7E0C2D1-D753-44AC-A0FD-43D308918C11 Q36270871-AB8042EC-F9B8-4C6D-A792-B86664793695 Q36360941-336989DD-3D7B-4D30-A2F9-66B645FF69D8 Q36382083-46305682-05B8-4EB0-A293-6BE9147A7B4C Q36792355-7B95B7F2-38E8-45AF-8295-23B4176A374A Q36879598-35A19881-F107-48DC-8235-F92367E456E0 Q37217464-E08D3D5A-C981-4CB1-A621-ED5AB842C5CB Q37477277-35BBEA63-58DB-4748-B621-EC5D093364EE Q37637243-E2913D35-F7FA-4B80-8DFF-16E43C63990E Q37702595-C441BCDD-23F7-4CB1-9ADB-E22891DD0DED Q37708987-3BEFABEA-CF9F-4A67-BC77-6146684A3B52 Q38436374-7AD71F27-76F2-4248-9138-94642194C393 Q38752773-C8F8FC94-4938-4934-866F-806CEF9204CC Q38864895-26935680-F741-4513-8706-C8BF74F7FEA6 Q39100773-CEFAC9D1-CBF4-4110-BB74-B25E2E63756C Q39123136-5F9C9BD5-6AA3-49FC-8856-225721E48B25 Q39455125-57A2708F-406C-41CC-ADA2-110AC7B08048 Q39630055-F6B3712C-1D7F-475A-85E7-6B2C11467457 Q39858747-1B81C3AC-B2FF-4AEB-932F-9A333B4CD5B3 Q39986343-F3D6E9BF-254B-43F6-91E4-5C814014D2C7 Q40200602-CD6D1A36-CD96-4D1C-BD19-DE7C8EAA3DD1 Q40600058-7C38C7AC-E5BD-469B-AE93-4E3749154CAB Q40600845-16FFB2FF-2844-4A81-BE8C-E5CBDB7CA080 Q41342988-D023F33E-56FE-4346-989B-1ADCB3FB7BC9 Q41621726-921551EB-6A0E-4FF1-9FD9-7F3D90350C2B Q41674640-F538B762-0A90-4257-ADF8-4883D26909C0 Q41921861-6B30B1BB-1D35-4AE3-AB05-DB3363732A04 Q42147221-442A1C29-156C-40AC-AE4F-0D63B19C11A7 Q42314594-EC3D1A4B-B10D-4AE9-A44B-F79BBADADB41 Q42546829-328727A2-7E66-45F9-BB4A-D2A4DDEDB22B Q45880681-6CD2DE20-0F0D-488B-9DB9-2E9957C88A36 Q46232926-6E6B996E-0709-4D56-A7E8-E02D7D66AA93 Q46750131-0C4FE54E-D773-4F94-9CAB-D1832328678B Q47350013-C197D5E0-5D43-4683-971F-1A4BA69F54CF Q47558500-5C22DD13-DF5C-48B4-A66A-4ADEB9B95BC0 Q48206047-F085A909-B7E7-49B6-B196-948B4DF5FACD Q48595289-BB69229E-B291-443B-9ABC-6A99ABB0022D

P2860

EGFR has a tumour-promoting role in liver macrophages during hepatocellular carcinoma formation.

http://www.wikidata.org/entity/Q34282375

description

2014 nî lūn-bûn

@nan

2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

EGFR has a tumour-promoting ro ...... ocellular carcinoma formation.

@ast

EGFR has a tumour-promoting ro ...... ocellular carcinoma formation.

@en

EGFR has a tumour-promoting ro ...... ocellular carcinoma formation.

@nl

type

label

EGFR has a tumour-promoting ro ...... ocellular carcinoma formation.

@ast

EGFR has a tumour-promoting ro ...... ocellular carcinoma formation.

@en

EGFR has a tumour-promoting ro ...... ocellular carcinoma formation.

@nl

prefLabel

EGFR has a tumour-promoting ro ...... ocellular carcinoma formation.

@ast

EGFR has a tumour-promoting ro ...... ocellular carcinoma formation.

@en

EGFR has a tumour-promoting ro ...... ocellular carcinoma formation.

@nl

P1433

Q34282375-4601D77E-4FBB-401E-BACD-13707F0A4929

P1476

Q34282375-B5F2AB94-40C4-4395-AEAD-2CB2FB253084

P2093

Q34282375-04DC2ABE-D2E8-4380-B059-46E696FA2DA4

Q34282375-15BAE94B-9907-4427-B3F5-E36FEC4CD360

Q34282375-38EBDC2B-3121-4AA4-B31D-FDC9855D23D0

Q34282375-41B6A46A-310B-4385-87EA-1C477B3DC1D5

Q34282375-4966E9A4-0F12-4CDB-9EE6-B2D74F1C82AC

Q34282375-5A103F3F-0853-4F33-ACBD-152C2E95CDA0

Q34282375-6317B34D-D54F-4004-B32B-4D2714D8F62B

Q34282375-64134551-399D-4BEC-BDA5-BF7DD700B077

Q34282375-B14609A6-6A07-4F09-8709-144212709140

Q34282375-BEF38900-F6C8-42E4-80C2-A7CDC3D449B2

P2860

Q34282375-00DFEEA7-4F0A-4A3B-9E7C-5645D0CDA3CC

Q34282375-08C6C425-3F34-4124-ACCA-AFEA8EDA60AB

Q34282375-0ACACD3B-52A2-4305-A06C-FC828719D11F

Q34282375-11DBF582-4A06-43FE-97C3-EBA507677FB5

Q34282375-14B6E5A4-C158-4AF9-B134-71DA2A20E409

Q34282375-18C6FE2D-121A-4A3A-95D3-699B24A149D2

Q34282375-1BB7257B-0579-4AA2-941A-5CF185F23D37

Q34282375-1BF1E218-9779-4760-9FC3-7A86DCAC2A01

Q34282375-20991906-FA10-40AA-950E-331158C8254B

Q34282375-22763EC1-35CD-40FD-9B3B-4D92A9D6A2DA

P2888

Q34282375-C07830BD-F969-410C-AC46-4357860A2A72

P304

Q34282375-12583D9C-9803-44E0-A96A-25867EDF86B0

P31

Q34282375-CD38D877-AED1-40E5-ABE0-C9B425E63EEF

P356

Q34282375-9C18F662-E213-4A0F-A7B1-349DD135AA91

P433

Q34282375-48B92E33-6F6B-4D26-B01A-8F971A63320E

P478

Q34282375-9E7551DF-B625-49F2-BBE2-54418894C6FE

P50

Q34282375-09CE832E-CFE5-4B07-B9D3-FE319975A40E

Q34282375-A2FE2463-67CF-461E-927B-857421920C96

Q34282375-FC3916B4-B568-471D-97E8-5B15EC96C84D

P577

Q34282375-7C537287-623B-464C-AF92-726863D68A06

P5875

Q34282375-155C54E6-D551-4E4F-8DF0-B57A34795E80

P6179

Q34282375-553BBA4F-5DBF-449C-BE16-58DC4D6FD50B

P698

Q34282375-BB1F7F6F-A3CE-43CE-8F4F-8B5BAFCE8200

P921

Q34282375-2C3DD774-7369-49EB-AFAA-B5A4DDE220CE

P932

Q34282375-006E1E36-8453-417A-8407-7C5372E13D28

P356

P1433

Nature Cell Biology

P1476

EGFR has a tumour-promoting ro ...... ocellular carcinoma formation.

@en

P2093

Anuradha Natarajan

http://www.w3.org/2001/XMLSchema#string

Hanane Lanaya

http://www.w3.org/2001/XMLSchema#string

Hongyang Wang

http://www.w3.org/2001/XMLSchema#string

Karin Komposch

http://www.w3.org/2001/XMLSchema#string

Lei Chen

http://www.w3.org/2001/XMLSchema#string

Liang Li

http://www.w3.org/2001/XMLSchema#string

Martina Hammer

http://www.w3.org/2001/XMLSchema#string

Michael Trauner

http://www.w3.org/2001/XMLSchema#string

Nicole Amberg

http://www.w3.org/2001/XMLSchema#string

Rainer Zenz

http://www.w3.org/2001/XMLSchema#string

P2860

Global cancer statistics

Inflammation and cancer

EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma

Immunity, Inflammation, and Cancer

Liver tumor development. c-Jun antagonizes the proapoptotic activity of p53

ADAMs: key components in EGFR signalling and development

The high mobility group (HMG) boxes of the nuclear protein HMG1 induce chemotaxis and cytoskeleton reorganization in rat smooth muscle cells

Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production

Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis

Transactivation of EGFR by LPS induces COX-2 expression in enterocytes.

P2888

P304

972-977

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NCB3031

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P50

Markus Peck-Radosavljevic

Stefanie K Wculek

P577

2014-08-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

265176309

http://www.w3.org/2001/XMLSchema#string

P6179

1002656499

http://www.w3.org/2001/XMLSchema#string

P698

25173978

http://www.w3.org/2001/XMLSchema#string

P921

P932

4183558

http://www.w3.org/2001/XMLSchema#string